Profile: Seikagaku Corp (4548.T)
4548.T on Tokyo Stock Exchange
Change (% chg)
SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.
10F, Marunouchi Center Bldg
CHIYODA-KU TKY 100-0005